MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Metamizol for the Treatment of Neoplastic Chronic Pain

First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6
Registration Number
NCT02181920

Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers

First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
23
Registration Number
NCT02182336

Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

Phase 1
Completed
Conditions
Prostatic Neoplasms
Interventions
First Posted Date
2014-07-08
Last Posted Date
2025-01-22
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
21
Registration Number
NCT02182219

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Phase 1
Completed
Conditions
Tumors
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02182128

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 207127 NA extended release (10% HPMC)
Drug: BI 207127 NA extended release (20% HPMC)
Drug: BI 207127 NA (TF-I)
Drug: BI 207127 NA (TF-II)
Drug: BI 207127 NA delayed release
Drug: BI 207127 NA extended release (15% PEO)
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
42
Registration Number
NCT02182414

Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

Phase 1
Completed
Conditions
Genital Neoplasms, Female
Interventions
First Posted Date
2014-07-08
Last Posted Date
2025-01-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
22
Registration Number
NCT02182245

Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 207127 NA powder for solution
Drug: Placebo
Drug: BI 207127 NA tablet
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
82
Registration Number
NCT02182388

Effects of Nevirapine on the Steady State Pharmacokinetics of Fluconazole in HIV Positive Patients

Phase 4
Completed
Conditions
HIV Infections
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02181946

Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women

Phase 3
Completed
Conditions
HIV Infections
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2648
Registration Number
NCT02181933

Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Placebo Respimat®
Drug: Berodual® via MDI, high dose
Drug: Berodual® via Respimat®, low dose
Drug: Placebo MDI
Drug: Berodual® via Respimat®, high dose
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
631
Registration Number
NCT02182479
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy